Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Broad based buying in markets
Thu, 13 Mar 11:30 am

After opening firm, the Indian indices are trading well above the dotted line in the morning session. Apart from software and pharma stocks, all sectoral indices are trading in the green. The buying interest is highest auto and banking stocks.

The BSE-Sensex is trading up 90 points and the NSE-Nifty is trading up 30 points. The BSE Mid Cap index is trading up 0.6% and the BSE Small Cap index is trading up 0.5%. The rupee is trading at 60.95 to the US dollar.

Software stocks are trading mixed today. While Tata Consultancy Services (TCS) is leading the gainers, Infosys is leading the losses. India's second largest software firm, Infosys, might need a longer time to get back to an Industry level growth rate, according to Chairman N.R. Narayana Murthy. At an investor conference, he has expressed his displeasure at the problems that the company is facing. As per him, Infosys has not been able to take any advantage of the depreciation of the rupee and that operating margins will remain under pressure in the near term. He expects growth to pick up only towards the end of FY15. He also indicated that the exodus of management talent from the company may not be over by saying that many more resignations could be expected. Infosys is trading down 7% today.

Indian Pharma stocks are trading on a mixed note today. While Sun Pharma is leading the losers, Orchid Chemicals and Panacea Biotech are trading firm today. As per a leading business daily, Sun Pharma has received an import alert from USFDA (United States Food and Drug Administration) for all products manufactured at its Karkhadi plant in Gujarat. It received an import alert and effectively a ban for all its API (active pharmaceutical ingredients) and formulations that it manufactures at its Gujarat plant. It may be noted that the move comes when its subsidiary, Caraco recently received USFDA approval for marketing of the company's Risperidone, a mental disorder drug. Also that the company has recently recalled over 2,500 drug bottles from US markets after it received customer's complaints. The company's financial impact on the ban of Gujarat plant is yet to be known. The ban is the result of the detention without physical examination of drugs which have not met the good manufacturing practices, according to the USFDA norms. Further, Ranbaxy and Wockhardt are already under the USFDA scanner for numerous import alerts.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Broad based buying in markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.